menu
    • menu
    [{"orgOrder":0,"company":"Leidos","sponsor":"Targovax","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"","productType":"Large molecule","year":"2020","type":"Collaboration","leadProduct":"Microbially derived peptides","moa":"Checkpoint","graph1":"Oncology","graph2":"Undisclosed","graph3":"Leidos","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"","sponsorNew":"Leidos \/ Targovax","highestDevelopmentStatusID":"1","companyTruncated":"Leidos \/ Targovax"},{"orgOrder":0,"company":"Leidos","sponsor":"Orgenesis","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"","productType":"Large molecule","year":"2020","type":"Collaboration","leadProduct":"Ranpirnase","moa":"","graph1":"Infections and Infectious Diseases","graph2":"Preclinical","graph3":"Leidos","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"","sponsorNew":"Leidos \/ Leidos","highestDevelopmentStatusID":"4","companyTruncated":"Leidos \/ Leidos"},{"orgOrder":0,"company":"Leidos","sponsor":"EpiVax","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"","productType":"Vaccine","year":"2021","type":"Collaboration","leadProduct":"Malaria Vaccine","moa":"CSP","graph1":"Infections and Infectious Diseases","graph2":"Discovery","graph3":"Leidos","amount2":0,"highestDevelopmentShortName":"Discovery","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Dosage Strength\/Form","sponsorNew":"Leidos \/ Leidos","highestDevelopmentStatusID":"2","companyTruncated":"Leidos \/ Leidos"}]

    Find Clinical Drug Pipeline Developments & Deals by Leidos

    Menu

    Leidos

    EVENTS

    • Webinars & Exhibitions

    DIGITAL CONTENT

    DEVELOPMENTS

    PharmaCompass
    Xls
    Filters Filter
    ×
    FILTER:
    filter
    Company Name
      filter

      Year

        filter

        DEALS // DEV.

          filter

          Country

            filter
            Sponsor
              filter

              Therapeutic Area

                filter

                Study Phase

                  filter

                  Deal Type

                    filter

                    Product Type

                      filter

                      Dosage Form

                        filter

                        Lead Product

                          filter

                          Target

                            Loading...
                            refresh Filters
                            refresh Reset Filter
                            refresh Reset Filter
                            price-trend All Developments

                            Therapeutic Area by Lead Product

                            Study Phase by Lead Product

                            Company by Lead Product

                            Top Deals by Deal Size (USD bn)

                            01

                            Leidos

                            U.S.A arrow
                            2024 ACI Convention
                            Not Confirmed

                            Leidos

                            U.S.A arrow
                            2024 ACI Convention
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Malaria Vaccine

                            Therapeutic Area : Infections and Infectious Diseases

                            Study Phase : Discovery

                            Recipient : EpiVax

                            Deal Size : Undisclosed

                            Deal Type : Collaboration

                            DEALS_DEV arrow-down

                            EpiVax Collaborates with Leidos on Malaria Vaccine Research, Series of Papers Published in Frontiers of Immuno...

                            Details : EpiVax was tapped by Leidos to conduct in silico T cell epitope prediction, for both HLA Class I and Class II epitopes in malaria vaccine blood stage antigens. The in silico predictions were subsequently used to inform ex vivo assessment by University of...

                            Brand Name : Undisclosed

                            Molecule Type : Vaccine

                            Upfront Cash : Undisclosed

                            November 17, 2021

                            Lead Product(s) : Malaria Vaccine

                            Therapeutic Area : Infections and Infectious Diseases

                            Highest Development Status : Discovery

                            Recipient : EpiVax

                            Deal Size : Undisclosed

                            Deal Type : Collaboration

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            02

                            Leidos

                            U.S.A arrow
                            2024 ACI Convention
                            Not Confirmed

                            Leidos

                            U.S.A arrow
                            2024 ACI Convention
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Ranpirnase

                            Therapeutic Area : Infections and Infectious Diseases

                            Study Phase : Preclinical

                            Recipient : Orgenesis

                            Deal Size : Undisclosed

                            Deal Type : Collaboration

                            DEALS_DEV arrow-down

                            Orgenesis and Leidos Collaborate on Potential Treatment for COVID-19

                            Details : Orgenesis has entered into a preliminary, non-binding term sheet with Leidos to develop and potentially obtain FDA marketing approval of Orgenesis’ Ranpirnase for the systemic treatment of patients suffering with SARS-CoV-2 the virus that causes COVID-...

                            Brand Name : Undisclosed

                            Molecule Type : Large molecule

                            Upfront Cash : Undisclosed

                            June 24, 2020

                            Lead Product(s) : Ranpirnase

                            Therapeutic Area : Infections and Infectious Diseases

                            Highest Development Status : Preclinical

                            Recipient : Orgenesis

                            Deal Size : Undisclosed

                            Deal Type : Collaboration

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            03

                            Leidos

                            U.S.A arrow
                            2024 ACI Convention
                            Not Confirmed

                            Leidos

                            U.S.A arrow
                            2024 ACI Convention
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : ONCOS viruses,Microbially derived peptides

                            Therapeutic Area : Oncology

                            Study Phase : Undisclosed

                            Sponsor : Targovax

                            Deal Size : Undisclosed

                            Deal Type : Collaboration

                            DEALS_DEV arrow-down

                            Targovax Enters Collaboration With Leidos to add Checkpoint Inhibitor Functionality to ONCOS Viruses

                            Details : Leidos and Targovax will investigate the technical feasibility, in vitro and in vivo immune modulatory, and anti-cancer properties of encoding Microtide™ checkpoint peptides in the ONCOS adenovirus backbone.

                            Brand Name : Undisclosed

                            Molecule Type : Large molecule

                            Upfront Cash : Undisclosed

                            June 04, 2020

                            Lead Product(s) : ONCOS viruses,Microbially derived peptides

                            Therapeutic Area : Oncology

                            Highest Development Status : Undisclosed

                            Sponsor : Targovax

                            Deal Size : Undisclosed

                            Deal Type : Collaboration

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth